Kymera Q3 2022 net loss $43M, cash $596M; board adds Sandor as Nicholson resigns

Kymera Therapeutics, Inc.

Q3 2022 net loss $43.0M ($0.81/sh) vs $28.6M in Q3 2021; collaboration revenue $9.6M vs $20.3M.
Cash, equivalents & investments $595.6M as of Sep 30, 2022; includes $150M Aug 2022 private placement.
KT-474 (IRAK4 degrader) patient cohort dosing complete; data to Sanofi in Q4, clinical update Dec 14, 2022.
Director Don Nicholson resigned Nov 3, 2022 (no disagreement); Victor Sandor appointed to Board same day.
KT-333 (STAT3 degrader) granted second orphan drug designation (CTCL); KT-253 IND on track for Q4 2022.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Victor Sandor

Director

KYMR · Kymera Therapeutics, Inc.

Effective: 2022-11-03
Filed: November 3, 2022, 7:59 PM ET

On November 1, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Victor Sandor, M.D. to join the Board, effective as of November 3, 2022.

Departed

Donald Nicholson

Director

KYMR · Kymera Therapeutics, Inc.

Effective: 2022-11-03
Successor: Victor Sandor
Filed: November 3, 2022, 7:59 PM ET

On October 31, 2022, Donald Nicholson, Ph.D., a member of the Board of Directors (the “Board”) of the Company and the Compensation Committee of the Board, notified the Company of his resignation from the Board and all committees thereof, effective November 3, 2022.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kymera Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Kymera Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Victor Sandor was appointed as Director at Kymera Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 1, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Victor Sandor, M.D. to join the Board, effective as of November 3, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Donald Nicholson resigned as Director at Kymera Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 31, 2022, Donald Nicholson, Ph.D., a member of the Board of Directors (the “Board”) of the Company and the Compensation Committee of the Board, notified the Company of his resignation from the Board and all committees thereof, effective November 3, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-276377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.